The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
Authors
Keywords
-
Journal
BONE MARROW TRANSPLANTATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-19
DOI
10.1038/s41409-019-0683-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups
- (2019) Makoto Murata et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation
- (2018) Nicolaus Kröger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT
- (2018) Donal P. McLornan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis
- (2018) Sharifah Shahnaz Syed Abd Kadir et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis
- (2018) Francesco Passamonti et al. Current Hematologic Malignancy Reports
- Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
- (2018) Kavita Raj et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group
- (2018) Francesca Patriarca et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
- (2017) J-C Hernández-Boluda et al. LEUKEMIA
- Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
- (2017) Lucia Masarova et al. LEUKEMIA RESEARCH
- A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
- (2017) Erden Atilla et al. Balkan Medical Journal
- Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group
- (2016) Giada Rotunno et al. AMERICAN JOURNAL OF HEMATOLOGY
- Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis
- (2016) Marie Robin et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
- (2016) Mohamed Shanavas et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Outcome Improvement After Allogeneic Stem-Cell Transplantation in Myelofibrosis
- (2016) Nicolaus Kröger Journal of Oncology Practice
- Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review
- (2016) Nosha Farhadfar et al. Journal of Oncology Practice
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
- (2015) N M Kröger et al. LEUKEMIA
- MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
- (2014) D. Rondelli et al. BLOOD
- The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
- (2014) J.-C. Hernandez-Boluda et al. HAEMATOLOGICA
- Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
- (2013) Animesh Pardanani et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Risk models predicting survival after reduced-intensity transplantation for myelofibrosis
- (2012) Haefaa Alchalby et al. BRITISH JOURNAL OF HAEMATOLOGY
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
- (2010) H. Alchalby et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started